(Q40896554)

24 September 2017

title

Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer (English)

1 reference

24 September 2017

Critz FA

1

1 reference

24 September 2017

Levinson K

2

1 reference

24 September 2017

Williams WH

3

1 reference

24 September 2017

Holladay D

4

1 reference

24 September 2017

Holladay C

5

1 reference

24 September 2017

Griffin V

6

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 May 1997

1 reference

24 September 2017

1 reference

24 September 2017

volume

49

1 reference

24 September 2017

issue

5

1 reference

24 September 2017

page(s)

668-672

1 reference

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

Failure of open radioactive 125iodine implantation to control localized prostate cancer: a study of 41 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

The PSA nadir that indicates potential cure after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

Estimating survival functions from the life table

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

Retropubic Implantation of Iodine 125 in the Treatment of Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900084-8

7 January 2021

10.1016/S0090-4295(97)00084-8

Identifiers

DOI

1 reference

24 September 2017

1 reference